Barker Gordon T, Cook Paul F, Schmiege Sarah J, Kahook Malik Y, Kammer Jeffrey A, Mansberger Steven L
Devers Eye Institute at Legacy Health, Portland, Oregon.
University of Colorado College of Nursing, Aurora, Colorado.
Am J Ophthalmol. 2015 Jun;159(6):1092-1099.e2. doi: 10.1016/j.ajo.2015.03.006. Epub 2015 Mar 17.
To assess the psychometric properties of a new version of the Glaucoma Treatment Compliance Assessment Tool, a survey evaluating health behavior and glaucoma adherence using constructs from the Health Belief Model.
Psychometric analysis.
We administered the 47-statement Glaucoma Treatment Compliance Assessment Tool to 201 participants who were using a single bottle of an ocular hypotensive agent, and objectively measured adherence with medication event monitoring system devices over 60 days. Adherence was the percentage of days with correctly timed bottle openings. We used principal components analysis to determine construct validity, Cronbach's alpha for internal consistency reliability, frequency analysis for floor and ceiling effects, and Spearman rho for test-retest reliability. We determined predictive validity using univariate and multiple regression.
The mean (±SD, range) adherence percentage was 79.9% (±18.5%, 20.3%-100.0%). Principal component analysis loaded 24 questions into 6 components that were consistent with the Health Belief Model. All 6 components had Cronbach's alpha reliability between 0.601 and 0.797. No statements had floor or ceiling effects, and all statements had acceptable test-retest reliability. Multiple regression analysis showed 4 Health Belief Model statements, white race, older age, and married marital status to be associated with higher adherence (adjusted R(2) = 0.27, P < .001).
The newest version of the Glaucoma Treatment Compliance Assessment Tool showed acceptable psychometric properties. With further refinement, clinicians and researchers could use it to examine factors related to adherence and measure improvement in adherence with a change in health behavior attitudes.
评估新版青光眼治疗依从性评估工具的心理测量特性,该调查使用健康信念模型中的结构来评估健康行为和青光眼治疗依从性。
心理测量分析。
我们对201名正在使用单瓶降眼压药物的参与者进行了包含47条陈述的青光眼治疗依从性评估工具的测试,并通过药物事件监测系统设备在60天内客观测量了依从性。依从性是指按时正确打开药瓶的天数百分比。我们使用主成分分析来确定结构效度,使用Cronbach's alpha来评估内部一致性信度,使用频率分析来评估地板效应和天花板效应,使用Spearman rho来评估重测信度。我们使用单变量和多元回归来确定预测效度。
平均(±标准差,范围)依从性百分比为79.9%(±18.5%,20.3%-100.0%)。主成分分析将24个问题归为6个与健康信念模型一致的成分。所有6个成分的Cronbach's alpha信度在0.601至0.797之间。没有陈述存在地板效应或天花板效应,并且所有陈述都具有可接受的重测信度。多元回归分析显示,健康信念模型的4条陈述、白人种族、年龄较大和已婚婚姻状况与较高的依从性相关(调整后的R(2)=0.27,P<.001)。
最新版青光眼治疗依从性评估工具显示出可接受的心理测量特性。经过进一步完善,临床医生和研究人员可以使用它来检查与依从性相关的因素,并衡量随着健康行为态度的改变依从性的改善情况。